FDA Approves Oral Combination of Decitabine and Cedazuridine Tablets with Venetoclax for Newly Diagnosed AML

esmo - Evidence for efficacy is based on the results from the Study ASTX727-07

AI Summary: The FDA has approved an oral combination (decitabine/cedazuridine plus venetoclax) as a treatment option for newly diagnosed acute myeloid leukemia patients who are older or unfit for intensive therapy. The approval offers an at-home alternative to frequent infusions, potentially reducing clinic visits and improving convenience for a vulnerable population.

#healthcare #pharmaceuticals #biotech #drugdevelopment #fda #oncology #cancerresearch #clinicaltrials

Nazanin Alemzadeh: A Rare Journey From AML to Solid Tumors Ending in Complete Remission

3 hrs / oncodaily

Amer Zeidan: A Co-first Author for a Clinical Trial That Resulted in FDA Approval on Acute Myeloid Leukemia

6 hrs / oncodaily

Talha Badar: An All-oral Option for Older/Unfit Newly Diagnosed AML

6 hrs / oncodaily

FDA-approved oral AML therapy could let older patients avoid monthly infusion visits

38 hrs / medicalxpress

FDA Approves Oral Combination of Decitabine and Cedazuridine Tablets with Venetoclax for Newly Diagnosed AML

2 days / esmo

Blog Post

FDA has approved the first all‑oral regimen for certain newly diagnosed acute myeloid leukemia (AML) patients: oral decitabine/cedazuridine tablets combined with venetoclax for patients who are older or otherwise unfit for intensive therapy. Approval is supported by data from Study ASTX727‑07 and the ASCERTAIN V trial, which reported strong response rates and favorable survival outcomes, and offers an at‑home alternative to repeated IV/infusion visits. Researchers including co‑authors Talha Badar and Amer Zeidan have highlighted the significance of this option for a vulnerable population. Sources: ESMO (ASTX727‑07) and MedicalXpress (ASCERTAIN V) — https://www.esmo.org/oncology-news/fda-approves-oral-combination-of-decitabine-and-cedazuridine-tablets-with-venetoclax-for-newly-diagnosed-aml ; https://medicalxpress.com/news/2026-06-fda-oral-aml-therapy-older.html

StackHealth RSS

You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Government Policy, Oncology, Digital Health, Genetics and look for the RSS link.

StackHealth Time Machine

More StackHealth